The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

As financial pressures intensify across health systems, Renton, Wash.-based Providence is grappling with the combined strain of high-cost therapies, slow biosimilar uptake, shrinking reimbursement and ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

The U.S. Food and Drug Administration (FDA) has approved STARJEMZA Injection, a biosimilar referencing Stelara (ustekinumab) Injection.

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection ...

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to ...

NEW JERSEY, NJ, UNITED STATES, May 26, 2025 /EINPresswire.com/ -- The global biosimilars market is experiencing robust growth as healthcare systems strive to improve patient access to life-saving ...

Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Spending on cancer drugs is expected to reach $441B globally in 2029 despite a slowdown later in the decade as key oncology ...